Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
|Solubility (25°C)||acetonitrile: water: ~1 mg/mL (60/40)|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Gerlinde F Plger, et al. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride
 G D Shanks, et al. Atovaquone and proguanil hydrochloride for prophylaxis of malaria
 P G Kremsner, et al. Atovaquone and proguanil hydrochloride for treatment of malaria
 M Beerahee. Clinical pharmacology of atovaquone and proguanil hydrochloride
 M Pudney, et al. Atovaquone and proguanil hydrochloride: a review of nonclinical studies
AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. AS1411 has anti-tumor activity.
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB).
MOPIPP is a novel indolebased chalcone, and vacuolin-1, is a non-lethal vacuoleinducing 2-propyl analog of MOMIPP. MOPIPP induces cellular vacuolization and increases autophagosomes numbers. MOPIPP also triggers methuosis, and interrupts glucose uptake and glycolytic metabolism. MOPIPP can cross the blood-brain barrier and shows efficacy in suppressing tumor progression agaisnt glioblastoma cells.
|Methuosis inducer 1
Methuosis inducer 1 is a potent methuosis inducer. Methuosis inducer 1 has anticancer activity.
|Dextran (Mw 150000)
Dextran is a multipurpose branched glucan, which can improve plasma colloid osmotic pressure, increase blood volume, reduce platelet adhesion, inhibit red blood cell aggregation, reduce blood viscosity, reduce peripheral circulation resistance, and unclog microcirculation.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.